Physician profile
Scott A Mcdaniel
NPI 1780623850
$5,348.93
in general payments reported to CMS, 2019-2025
49 companies · $969 in 2025
The $969 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $204 · 2021: $1,184 · 2022: $389 · 2023: $738 · 2024: $853 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $777.73 | 2021 | |
| Celgene Corporation | $492.95 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $431.47 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $385.96 | 2019-2025 | |
| Exelixis INC. | $237.83 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $207.40 | 2019-2025 | Welireg, Keytruda Qlex, Keytruda |
| Genentech USA, INC. | $149.18 | 2019-2025 | Phesgo, Polivy, Tecentriq |
| Abbvie INC. | $148.49 | 2022-2025 | |
| Gilead Sciences, INC. | $145.39 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $134.27 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $132.04 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Eisai INC. | $128.62 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $126.27 | 2019-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $122.78 | 2019-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $116.72 | 2019-2025 | Vyloy, Padcev, Xtandi |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $109.68 | 2019-2025 | Onivyde, Somatuline Depot |
| Janssen Biotech, INC. | $109.19 | 2022-2025 | Darzalex, Erleada, Tecvayli |
| Beigene USA, INC. | $103.84 | 2021-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $102.26 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $98.99 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pharmacyclics LLC, An Abbvie Company | $96.25 | 2019-2023 | Imbruvica |
| Incyte Corporation | $78.71 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Array Biopharma INC | $78.30 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $75.08 | 2019-2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $73.32 | 2021-2024 | Jemperli, Ojjaara, Zejula |
| Amgen INC. | $59.12 | 2019-2022 | |
| Tesaro, INC. | $54.73 | 2019 | |
| Stemline Therapeutics INC. | $54.11 | 2019-2025 | Orserdu |
| Lilly USA, LLC | $50.05 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.49 | 2019-2025 | |
| Kyowa Kirin, INC. | $43.34 | 2019-2025 | |
| Springworks Therapeutics, INC. | $35.06 | 2025 | Ogsiveo |
| Epizyme, INC. | $35.04 | 2021 | |
| Seagen INC. | $34.10 | 2023 | Tukysa, Padcev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.44 | 2019 | |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Kite Pharma, INC. | $26.58 | 2021-2023 | |
| Dendreon Pharmaceuticals LLC | $23.41 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $21.17 | 2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $20.26 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $19.04 | 2025 | Brukinsa |
| Coherus Oncology, INC. | $16.30 | 2022 | |
| Servier Pharmaceuticals LLC | $16.28 | 2025 | |
| Global Blood Therapeutics, INC. | $15.02 | 2022 | |
| Karyopharm Therapeutics INC. | $14.29 | 2020 | |
| Azurity Pharmaceuticals, INC. | $13.73 | 2025 | Danziten, Vivimusta |
| Apellis Pharmaceuticals, INC. | $13.58 | 2024 | Empaveli |
| Puma Biotechnology, INC. | $11.22 | 2019 | |
| Clovis Oncology, INC. | $6.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.